For research use only. Not for therapeutic Use.
Morniflumate（Cat No.:I008134）, also referred to as UP-164 and Morniflu, is a nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for the treatment of inflammation. It belongs to the class of NSAIDs and exhibits anti-inflammatory, analgesic, and antipyretic properties. Morniflumate is utilized to alleviate symptoms associated with various inflammatory conditions, including rheumatoid arthritis, osteoarthritis, and acute musculoskeletal disorders. As an NSAID, it works by inhibiting the production of inflammatory mediators, such as prostaglandins, thereby reducing inflammation and providing relief to patients.
| Catalog Number | I008134 |
| CAS Number | 65847-85-0 |
| Synonyms | Morniflumate; UP-164; UP 164; UP164; Morniflu; Niflam;2-morpholinoethyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate |
| Molecular Formula | C19H20F3N3O3 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate |
| InChI | InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24) |
| InChIKey | LDXSPUSKBDTEKA-UHFFFAOYSA-N |
| SMILES | C1COCCN1CCOC(=O)C2=C(N=CC=C2)NC3=CC=CC(=C3)C(F)(F)F |
| Reference | </br>1:Comparative pharmacokinetic and bioequivalence evaluation of two formulations of morniflumate 350-mg tablets in healthy male subjects . Lee H, Yim SV, Kim BH, Lee S.Int J Clin Pharmacol Ther. 2017 Jan;55(1):95-101. doi: 10.5414/CP202678. PMID: 27841153 </br>2:Efficacy and safety of morniflumate for the treatment of symptoms associated with soft tissue inflammation. Cremonesi G, Cavalieri L.J Int Med Res. 2015 Jun;43(3):290-302. doi: 10.1177/0300060514567212. Epub 2015 Apr 28. Review. PMID: 25921871 </br>3:Simultaneous determination of morniflumate and its major active metabolite, niflumic acid, in human plasma by high-performance liquid chromatography in stability and pharmacokinetic studies. Cho HY, Park GK, Lee YB.Biomed Chromatogr. 2013 Nov;27(11):1438-43. doi: 10.1002/bmc.2940. Epub 2013 May 30. PMID: 23722315 </br>4:Short-term tolerability of morniflumate in patients with cutaneous hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Mero F, Nettis E, Aloia AM, Di Leo E, Ferrannini A, Vacca A.Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):247-50. PMID: 23527729 </br>5:Morniflumate-induced urticaria-angioedema. Matheu V, Sierra Z, Gracia MT, Caloto M, Alcazar MM, Martinez MI, Zapatero L.Allergy. 1998 Aug;53(8):812-3. No abstract available. PMID: 9722233 Free Article</br>6:[Lyell syndrome following administration of erythromycin-sulfafurazole and morniflumate]. Raymond F, Paillat A, Gambert C, Garnier P.Arch Pediatr. 1995 May;2(5):494-5. French. No abstract available. PMID: 7640747 </br>7:Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Civelli M, Vigano T, Acerbi D, Caruso P, Giossi M, Bongrani S, Folco GC.Agents Actions. 1991 Jul;33(3-4):233-9. PMID: 1659152 </br>8:[A new anti-inflammatory-analgesic-antipyretic, morniflumate, in the treatment of chronic recurring bronchitis]. Melica A, Donateo L, Gerardi R, Parenti M.Riv Eur Sci Med Farmacol. 1991 Feb-Apr;13(1-2):51-60. Italian. PMID: 1796197 </br>9:[Treatment of acute inflammatory pathology of the upper airway with morniflumate]. Marchioni CF, Livi E, Oliani C, Guerzoni P, Corona M.Riv Eur Sci Med Farmacol. 1990 Dec;12(6):347-57. Italian. PMID: 2132289 </br>10:Double-blind, placebo-controlled multicentre trial of the efficacy and tolerance of morniflumate suppositories in the treatment of tonsillitis in children. Manach Y, Ditisheim A.J Int Med Res. 1990 Jan-Feb;18(1):30-6. Erratum in: J Int Med Res 1990 Mar-Apr;18(2):preceding 75. PMID: 2110537 |
